Published in Oncology Business Week, July 3rd, 2005
ARQ 650RP is ArQule's second major platform for oncology drug discovery, distinct from the company's E2F platform, which is partnered with Roche and includes a lead compound under investigation in several clinical trials and a second-generation compound in late preclinical development. ArQule retains ownership of all compounds based upon the ARQ 650RP platform, including ARQ 197.
"I am pleased that we have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.